# Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

> **NCT02120976** · PHASE1 · TERMINATED · sponsor: **Akros Pharma Inc.** · enrollment: 85 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** JTT-252 or Placebo
- **DRUG:** JTT-252

## Key facts

- **NCT ID:** NCT02120976
- **Lead sponsor:** Akros Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2015-02
- **Final completion:** 2015-03
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2015-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120976, "Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02120976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*